$BCLI re-read about 10x. Another completely overblown downturn. FDA is simply saying they wouldn’t traditionally support a BLA that fails Primary and secondary. It’s just a high level recap of P3. Already known. A submission for BLA for actual Approval would include the totality of evidence, the subgroup, doc analysis, and to there point - upcoming peer reviewed analysis.